Our Company
Behind every elevated PSA is a person who deserves more than uncertainty.
Origins
5Q was born from more than a decade of academic research at the intersection of optical imaging, ultrasound physics, and molecular diagnostics.
The core technologies behind 5Q were developed in leading research laboratories and supported by extensive peer-reviewed work. What began as academic innovation was intentionally translated into clinical tools—designed not for theory, but for real patients, real workflows, and real decisions.
From the beginning, the focus has been practical impact: moving advanced science out of the lab and into everyday clinical use, starting with prostate cancer and expanding rapidly into other high-impact cancers.
About our Leadership
5Q is led by a multidisciplinary team of scientists, clinicians, and operators with deep experience in cancer biology, medical imaging, diagnostics, and healthcare commercialization.
Our leadership includes:
• Executives with experience building and scaling healthcare and diagnostics companies
• Scientific leaders responsible for the underlying technology and intellectual property
• Clinical advisors who actively practice medicine and guide real-world implementation
This combination ensures that 5Q remains grounded in rigorous science, aligned with clinical reality, and focused on execution.
ProstateDx™ is a laboratory developed test (LDT) and has not been cleared or approved by the U.S. Food and Drug Administration (FDA). Testing is performed as a laboratory developed test (LDT) under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) to conduct high-complexity testing.